Gastrointestinal Tract,
Journal Year:
2023,
Volume and Issue:
1
Published: Dec. 26, 2023
This
review
would
delve
into
the
latest
developments
in
molecular
landscape
of
pancreatic
cancer
and
how
this
knowledge
can
be
applied
to
treatments.
It
could
particularly
highlight
emerging
therapies
like
immunotherapy,
genetic
profiling
analyses,
targeted
treatment
approaches.
Furthermore,
it
assess
recent
research
on
early
detection
prevention
strategies
for
cancer,
providing
insights
future
outlook.
significant
interest
value
researchers,
healthcare
professionals,
anyone
seeking
understand
current
state
innovations.
Cancers,
Journal Year:
2024,
Volume and Issue:
16(8), P. 1589 - 1589
Published: April 20, 2024
Pancreatic
ductal
adenocarcinoma
(PDAC),
one
of
the
deadliest
cancers,
presents
significant
challenges
in
diagnosis
and
treatment
due
to
its
aggressive,
metastatic
nature
lack
early
detection
methods.
A
key
obstacle
PDAC
is
highly
complex
tumor
environment
characterized
by
dense
stroma
surrounding
tumor,
which
hinders
effective
drug
delivery.
Nanotechnology
can
offer
innovative
solutions
these
challenges,
particularly
creating
novel
delivery
systems
for
existing
anticancer
drugs
PDAC,
such
as
gemcitabine
paclitaxel.
By
using
customization
methods
incorporating
conjugated
targeting
ligands,
tumor-penetrating
peptides,
therapeutic
nucleic
acids,
nanoparticle-based
enhance
solubility,
extend
circulation
time,
improve
targeting,
control
release,
thereby
minimizing
side
effects
toxicity
healthy
tissues.
Moreover,
nanoparticles
have
also
shown
potential
precise
diagnostic
PDAC.
This
literature
review
will
delve
into
targeted
mechanisms,
pathways,
approaches
treating
pancreatic
cancer.
Additional
emphasis
placed
on
study
systems,
with
a
brief
mention
those
clinical
trials.
Overall,
overview
illustrates
advances
nanomedicine,
underscoring
role
transcending
constraints
conventional
therapies
diagnostics.
Biomedicine & Pharmacotherapy,
Journal Year:
2023,
Volume and Issue:
165, P. 115151 - 115151
Published: July 18, 2023
Ovarian
cancer
is
a
highly
lethal
disease
that
affects
women.
Early
diagnosis
and
treatment
of
women
with
early-stage
improve
the
probability
survival.
Unfortunately,
majority
ovarian
are
diagnosed
at
advanced
stages
3
4
which
makes
challenging.
While
patients
respond
to
first-line
treatment,
i.e.
cytoreductive
surgery
integrated
platinum-based
chemotherapy,
rate
recurrence
very
high
available
options
for
recurrent
not
curative.
Thus,
there
need
more
effective
cancer.
Targeted
drug
conjugate
systems
have
emerged
as
promising
therapeutic
strategy
These
provide
opportunity
selectively
deliver
potent
chemotherapeutic
drugs
cancer,
sparing
healthy
normal
cells.
effectiveness
improved
systemic
toxicity
greatly
reduced.
In
this
review,
different
targeted
been
or
being
developed
will
be
discussed.
International Journal of Molecular Sciences,
Journal Year:
2025,
Volume and Issue:
26(6), P. 2798 - 2798
Published: March 20, 2025
Combination
chemotherapy
is
preferred
for
the
treatment
of
ovarian
cancer
(OC).
Systemic
toxicity,
however,
frequently
limits
effectiveness
treatment.
Polymer–drug
conjugates
(PDCs)
containing
synergistic
combinations
chemotherapeutic
drugs
can
be
used
to
enhance
therapeutic
efficacy.
We
earlier
reported
use
a
strain-promoted
[3
+
2]
azide–alkyne
cycloaddition
(SPAAC)-mediated
polymerization
method
preparation
single-drug
PDCs.
In
this
report,
was
prepare
gemcitabine–doxorubicin
combination
PDC.
The
PDC
had
high
molecular
weight
(Mw
1360
kDa)
and
drug
loading
(36.6%
gemcitabine;
7.0%
doxorubicin).
It
demonstrated
cathepsin
B-catalyzed
release
at
pH
5.0
good
hydrolytic
stability
7.4.
index
analysis
free
gemcitabine
doxorubicin
showed
concentration-dependent
synergism
(combination
<
1)
in
OVCAR-3
OC
cells.
Compared
individual
(the
concentration
that
inhibited
50%
growth
(IC50)
>
50
µg/mL)
(IC50
=
1.79
µg/mL),
0.99
greater
cytotoxicity
against
cells
less
cytotoxic
than
equivalent
0.11
µg/mL).
promising
targeted
OC.
Pharmaceutics,
Journal Year:
2024,
Volume and Issue:
16(2), P. 283 - 283
Published: Feb. 16, 2024
Pancreatic
ductal
adenocarcinoma
(PDAC)
presents
a
formidable
challenge
with
high
lethality
and
limited
effective
drug
treatments.
Its
heightened
metastatic
potential
further
complicates
the
prognosis.
Owing
to
significant
toxicity
of
current
chemotherapeutics,
compounds
like
[Met5]-enkephalin,
known
as
opioid
growth
factor
(OGF),
have
emerged
in
oncology
clinical
trials.
OGF,
an
endogenous
peptide
interacting
OGF
receptor
(OGFr),
plays
crucial
role
inhibiting
cell
proliferation
across
various
cancer
types.
This
vitro
study
explores
anticancer
efficacy
newly
synthesized
bioconjugate
synergy
classic
chemotherapeutic
agent,
gemcitabine
(OGF-Gem).
The
delves
into
assessing
impact
OGF-Gem
conjugate
on
inhibition,
cycle
regulation,
induction
cellular
senescence,
apoptosis.
Furthermore,
antimetastatic
was
demonstrated
through
evaluations
using
blood
platelets
AsPC-1
cells
light
aggregometer.
In
summary,
this
article
demonstrates
cytotoxic
innovative
pancreatic
both
2D
3D
models.
We
highlight
alone
effectively
ex
vivo
tumor
cell-induced
platelet
aggregation
(TCIPA)
process,
phenomenon
not
observed
Gem
alone.
confirmed
hemocompatibility
reinforces
its
promising
potential.
anticipate
that
conjugation
strategy
will
open
avenues
for
development
potent
agents.
